Annual General Meeting of Infant Bacterial Therapeutics AB (publ)

 

The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2017 voted to approve the following resolutions:

 

  • *  Adoption of the annual report
  • *  Discharge from liability granted for the Board members and Managing Director
  • *  That no dividend is given
  • *  Re-election of Board members Peter Rothschild, Jan Annwall, Anders Ekblom and Margareta Hagman.
  • *  Election of Eva Idén and Anthon Jahreskog as new board members
    •     -  Eva Idén, born 1966, is a Civil Engineer in Chemical Engineering from Chalmers University of Technology. She has many years of experience from senior positions in Astra and AstraZeneca. She is currently acting as a consultant in leadership and organizational development and the business owner of Better & Beyond AB as well as partner in Inflecto AB.
    •     -  Anthon Jahreskog, born 1980, holds a Master's degree in Economics and received a Master's degree in Financial Management at the University of Cape Town. He is today acting as business strategist and adviser in various industries. He was up until July 2015 the Chief Operating Officer, Fund Linked Products, Credit Suisse Investment Bank, London. Anthon has several years of experience in the international financial market and his core expertise is in finance, strategic business planning, cost efficiency and analysis.
  • *  Re-election of Peter Rothschild as chairman of the board
  • *  Re-election of the registered auditing company Deloitte AB
  • *  Board member compensation in the amount of SEK 200,000 to the Chairman of the Board and an additional remuneration for the work carried out as working chairman in the amount of SEK 400,000 and SEK 100,000 to other members of the Board who are not employed by the Company.
  • *  That audit fees shall be paid according to approved invoices
  • *  On a Nominating Committee in accordance with the Nomination Committee's proposal
  • *  On new issuance allowance in accordance with the Board's proposal under which the Board may decide to issue new B shares on market terms. In the case of issues that deviate from shareholders' preferential rights, the Board shall not have the mandate to increase the share capital by more than twenty (20) percent in relation to the share capital that exists when the issue authorization is first taken for a targeted issue.
  • *  About the inclusion of an incentive program in accordance with the Board's proposal whereby no more than 280,000 warrants are issued to a subsidiary formed by the company specifically for the incentive program. Of these options, 200,000 will be transferred to the company's existing CEO, senior executives and employees, or wholly owned companies. 80,000 warrants can be transferred to future employees. Each warrant shall entitle the holder to subscribe for a new Class B share in the company at a subscription price equal to SEK 300.

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

www.ibtherapeutics.com

 

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North. The information was submitted for publication, through the agency of the contact person set out above, at 18.00 CET on May 4, 2017.

 

See the press release in both English in Swedish:

PR 20170504 AGM English

PR 20170504 AGM Swedish

 

 

May 4, 2017

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2017

Message from the CEO

IBTs operations will during the current year be focused on completion of the ongoing Phase ll study and planning of the following clinical Phase lll study of IBP-9414. As previously stated, a Phase lll study will require additional capital. IBT is actively working with several potential financing possibilities and is seeking partners who can contribute resources for the continuing development program. We expect to gain improved understanding how agencies and experts view our new project IBP-1016, we also expect to receive our Phase II results of IBP-9414 (NCT02472769), and plan to apply for the main marketplace, Nasdaq Stockholm.

 

Staffan Strömberg

CEO

Financial summary Q1 2017

 

 

Significant events during the first quarter 2017

 *In January 2017, all 120 patients were included in the Company’s phase ll clinical trial in IBP-9414 (NCT02472769)

 

 *IBT’s series B shares were listed on Nasdaq First North Premier on March 14

 

Significant events after the reporting period

 *No significant events have occurred after the reporting period

 

Infant Bacterial Therapeutics AB (publ) Interim Report  is now available on the companies website www.ibtherapeutics.com.

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

www.ibtherapeutics.com

 

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North. The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on May 4, 2017.

 

See the full press release in both English and Swedish

PR 20170504 Q1 English

PR 20170504 Q1 Swedish

 

See the Interim Report Q1 2017 in both English and Swedish

IBT Interim Report Q1 2017 English

IBT Interim Report Q1 2017 Swedish

 

May 4, 2017

Infant Bacterial Therapeutics AB (publ) Annual Report for 2016 has now been published

 

Infant Bacterial Therapeutics AB (publ) Annual Report 2016 is now available on the companies website www.ibtherapeutics.com.

 

A physical copy of the Annual Report can also be requested by contacting IBT at the address info@ibtherapeutics.com .

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

www.ibtherapeutics.com

 

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on April 6, 2017.

 

See Press Release in both English and Swedish

IBT Press Release 20170406 (English)

IBT Press Release 20170406 (Swedish)

 

See Annual Report 2016 in both English and Swedish

IBT Annual Report 2016 English

IBT Annual Report 2016 Swedish

April 6, 2017

Annual General Meeting of Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting at 2:00 p.m. on Thursday, 4 May 2017, at Citykonferensen Ingenjörshuset, Malmskillnadsgatan 46, Stockholm.

 

Right to participate

In order to participate in the Annual General Meeting (AGM), shareholders must be recorded in the register of shareholders maintained by Euroclear Sweden AB no later than Thursday 27 April 2017 and must provide notice of participation to the company no later than Thursday 27 April 2017. Notification can be made by mail to Infant Bacterial Therapeutics AB (publ), Bryggargatan 10, 111 21 Stockholm, Sweden, by telephone +46 (0)8-410-145 55, or by e-mail to info@ibtherapeutics.com.

 

The notification should include the shareholder’s name, personal or corporate identity number, address, telephone number, registered shareholding and the names of any proxies or assistants.

 

In order to vote in the AGM, shareholders whose shares are registered in the name of a trustee must temporarily re-register the shares in their own name. Such registration, which may be temporary, must be completed Thursday 27 April 2017.

 

Form of proxy

Shareholders who are represented by a proxy must submit a dated form of proxy. If the form of proxy is submitted by a legal entity, a copy of the certificate of registration or other proof of authorisation for the legal entity must be attached. A form of proxy is available on the Company's website, ibtherapeutics.com or can be requested by sending an email to info@ibtherapeutics.com. An original form of proxy and, where appropriate, a certificate of registration or other proof of authorisation should be received by the company at the above address no later than Thursday 27 April 2017.

 

Proposed agenda

- Opening of the Meeting.

- Election of the Chairman of the Meeting.

- Drawing up and approval of the voting list.

- Election of one or two persons to attest the minutes of the Meeting

- Approval of the agenda.

- Determination as to whether the Meeting has been duly convened.

- Address by the CEO.

- Presentation of the annual report and the audit report.

- Resolution’s regarding: * Adoption of the income statement and balance sheet, * Appropriation of the company’s earnings according to the adopted balance sheet, * Discharge from liability for the Board of Directors and the President.

- Resolution regarding the number of Board members.

- Determination of fees to be paid to the Board of Directors and auditors.

- Election of Board members. * Peter Rothschild * Jan Annwall * Anders Ekblom * Margareta Hagman * Eva Idén * Anthon Jahreskog

- Election of the Board Chairman.

- Election of Auditor

- Resolution regarding the Nominating Committee

- The Board’s proposal for resolution regarding mandate for a directed new issuance of ordinary shares.

- The Board’s proposal for resolution regarding Employee Warrant plan.

- Closing of the Meeting

 

Resolutions, etc.

The Nominating Committee’s proposals regarding items 2 and 10-15 in the agenda.

The Nominating Committee consists, except for the Board Chairman, Peter Rothschild, of Per-Erik Andersson, (representing Annwall & Rothschild Investment AB, the company’s largest shareholder), Sebastian Jahreskog, who via direct and indirect ownership is the second largest shareholder and Jannis Kitsakis (representing Fjärde AP-fonden).

 

The Nominating Committee proposes the following:

Item 2 - Election of the Chairman of the Meeting

Attorney Erik Sjöman.

 

Item 10 - Resolution regarding the number of Board members

Six regular Board members with no deputies.

 

Item 11 - Determination of fees to be paid to the Board of Directors and auditors

The Board Chairman shall receive SEK 200,000 and additional compensation of SEK 400,000 for work carried out for the company in the capacity as Executive Chairman. The other Board members not employed by the company shall receive SEK 100,000 each. Auditors’ fees shall be paid according to approved account.

 

Item 12 - Election of Board members

Re-election of Peter Rothschild, Jan Annwall, Anders Ekblom, and Margareta Hagman.

 

Election of Eva Idén and Anthon Jahreskog.

 

Eva Idén, born 1966, has a Masters in Chemical Engineering from Chalmers University.  She has experience from management roles in Astra and AstraZeneca.  Eva is currently working as a management consultant in Leadership and Organisational development, and in the capacity as owner of Better & Beyond AB and partner in Inflecto AB. Eva Idén is independent of the company and its management and owns 30 shares in Infant Bacterial Therapeutics AB (publ).

 

Anthon Jahreskog, born 1980, received his Master's degree in Financial Management from the University of Cape Town. He is currently working as a business strategist and advisor in various industries. Until July 2015 was the Chief Operating Officer, Fund Linked Products, Credit Suisse Investment Bank, London. Anthon has several years of experience in the international financial market and his core expertise is in finance, strategic business planning, cost efficiency and analysis. Anthon Jahreskog is independent of the company and its management but not in relation to major shareholders. Anthon Jahreskog is a member of the Board of Directors of BioGaia AB (publ) and Board Member of SparkHub Ltd. Furthermore, Anthon Jahreskog is owner and member of the Board of Directors of Hamilton Park Consulting Ltd. Anthon Jahreskog is independent of the Company and does not own shares in Infant Bacterial Therapeutics AB (publ).

 

A detailed description of the members of the Board proposed for re-election is provided in the 2016 annual report and on the company’s website ibtherapeutics.com.

 

Item 13 - Election of the Board Chairman

Re-election of Peter Rothschild

 

Item 14 – Election of Auditor

Re-election of Deloitte AB.

 

Item 15 - Resolution regarding the Nominating Committee

The Board Chairman shall convene the three largest shareholders in the company, in terms of voting power, each of which shall have the right to appoint a member to form the Nominating Committee together with the Board Chairman. In determining the composition of the Nominating Committee, the largest shareholders in terms of voting power shall be based on the ownership conditions at 30 June 2017. The Nominating Committee shall be chaired by the member representing the largest shareholder on this date. If any of the three largest shareholders should waive this right, the shareholder next in order of voting power shall be given the opportunity to appoint a member to the Nominating Committee. The names of the shareholder representatives shall be announced as soon as they are appointed, although no later than six months prior to the 2018 Annual General Meeting. The mandate period of the Nominating Committee shall extend until such time as the new Nominating Committee has been appointed.

 

In the case that the shareholder that the member represents should no longer be one of the three largest shareholders in terms of voting power, the Nominating Committee, if it finds it appropriate, could dismiss that member and give a representative of the shareholder that is next in terms of voting power the opportunity of being elected. In the case that a designated member of the committee for any other reason leaves the Nominating Committee, the shareholder who has appointed the member, shall be entitled to appoint a new representative to the committee. If such shareholder declines to appoint a new representative, the Nomination Committee should, if it finds it appropriate, considering the remaining term of office, ask the shareholder that is next in terms of voting power if it wishes to appoint a representative to the Nominating Committee.

 

The Nominating Committee shall prepare proposals on the following matters to be put before the 2018 AGM for decision:

 

- proposal for election of a Chairman of the AGM - proposal for election of Board members - proposal for election of the Board Chairman - proposal for determination of Board fees - proposal for election of auditor - proposal for determination of auditor’s fees - proposal for a resolution regarding the Nominating Committee ahead of the 2019 AGM.

 

The Board’s proposals for resolution regarding items 9b, 16 and 17 on the agenda.

Item 9 b – Appropriation regarding the company’s earnings

The Board of Directors and CEO propose that no dividend shall be paid for fiscal year 2016.

 

Item 16 - The Board’s proposal for resolution regarding mandate for a directed new issuance of shares

The Board of Directors proposes that the AGM approve that the Board of Directors have a mandate to, on one or more occasion until the next AGM, issue new B-class shares. The Board of Directors will be able to decide on a new issuance of shares with deviation from the shareholders’ pre-emption rights. This authorisation is to include the right to issue shares with cash payment, payment by contribution in kind or payment by way of set-off, and otherwise subject to conditions as set out in Chapter 2, Section 5, second paragraph 1–3 and 5 of the Swedish Companies Act.

 

The decision by the Board of Directors in relation to a new share issue that deviates from shareholders’ pre-emption rights (directed issue) shall not exceed a twenty percent increase in share capital in relation to the share capital when the mandate for new issue is first utilised by the Board of Directors.

 

The share issue under this authorization shall be on market terms. The Board shall have the right to determine the conditions of the issue under this authorization as well as mandate to determine who has the right to subscribe for shares. The purpose of the authorization is to provide the Board with flexibility in efforts to ensure that the company in an appropriate manner, has additional capital to finance the company's ongoing clinical activities, and to enable a broadening of the owner base of the company.

 

Item 17 – Incentive program

The Board of Directors proposes that the AGM approve an incentive plan via i) direct placement of warrants to a subsidiary company especially established for this purpose ("Subsidiary"), and ii) authorization of transfer of warrants from the Subsidiary to participants in the program, in accordance with the following terms.

 

The Board believes that it is important and in the interest of all shareholders that the employees, who are deemed to be important for the company's further development, have a long-term interest in the appreciation of the shares in the company. A personal long-term ownership commitment can be expected to contribute to an increased interest in the company's operations and earnings and raise participants' motivation and alignment of interests with the company and its shareholders.

 

Based on the existing number of shares, the dilution resulting from the proposed incentive program, assuming that all warrants are exercised for subscription of new Class B shares, will account for circa 4.84 percent of the shares and approximately 3.60 percent of the votes.

 

Directed issue of warrants to the Subsidiary

 

A maximum of 280 000 warrants will be issued. The right to subscribe for the warrants shall, with deviation from the shareholders' preferential rights, be by the company's wholly owned Subsidiary.

 

The reason for the deviation from shareholders' preferential rights is that the issue is part of the implementation of the incentive program, with which the company's employees are given the opportunity to share in the positive development of the company. The existence of such a program is expected to increase the ability to attract and retain qualified employees.

 

Subscription of warrants shall be made through the subscription list by 18 May 2017. The Board of Directors shall be entitled to extend the subscription period. The warrants are issued free of charge.

 

Each warrant will entitle the holder to subscribe for one new share in the Company at an issue price of 300 SEK. Subscription of B shares with subscription warrants shall be made in accordance with the terms of the warrants as of April 3, 2022 and May 3, 2022.

 

If all warrants are exercised for subscription of B-shares, the registered share capital will increase by approximately 76 313.16 SEK (given current ratio and provided that no conversion is done according to the option terms).

 

B shares issued as a result of the subscription shall entitle to dividends on the dividend record date occurring after the share capital is registered with the “Bolagsverket” and B-shares have been recorded in the share register kept by Euroclear Sweden AB.

 

Approval of transfer of warrants from the Subsidiary to participants in the incentive program

 

The Board proposes that the Meeting resolves to approve that the Subsidiary transfers a maximum of 200,000 warrants to the company's current CEO, senior executives and employees, or to those persons wholly owned companies, according to the following principles. The transfer can also be made to future employees.

 

Category A - CEO: no more than 70,000 warrants.

 

Category B – other senior executives: 100 000 warrants to the group as a whole and not more than 50,000 warrants per person in the group.

 

Category C - other employees: a maximum of 30 000 warrants to the group as a whole and not more than 10,000 warrants per person in the group.

 

The transfer should also be made to prospective employees, or those people wholly owned companies, and more than 80 000 warrants to be used for this purpose. The principles laid down for different categories above shall also apply in relation to such transfers.

 

The warrants shall be transferred on market terms at a price established on the basis of an estimated market value of the warrants at the time of the transfer of the Black & Scholes valuation model (option premium). The calculation of the option premium shall be performed by an independent valuation expert.

 

In addition, a so-called pre-emption agreement will be made under which the holder shall be obliged to offer the company to acquire the warrants, or a portion of them, under certain conditions.

 

A valid resolution requires approval of shareholders representing at least nine tenths of both the votes cast and the shares represented at the meeting.

 

_________________________________________________________________________

 

Number of shares / votes and documentation, etc.

 

The total number of shares amounts to 5,503,638, of which 222 198 A shares and 5,281,440 B shares, with a total number of votes 7,503,420.

 

At the AGM, if any shareholder should so request and the Board assesses that this can be done without significant damage to the company, the Board of Directors and the President shall provide information about conditions that could affect the assessment of items on the agenda and conditions that could affect the assessment of the company’s or a subsidiary’s financial situation and the company’s relationship to other group companies.

 

The Annual Report and other key documents will be available at the company and on www.ibtherapeutics.com later than three weeks before the meeting and will be sent free of charge to shareholders who so request and state their address.

 

This is a translation of the Swedish version of the Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics AB (publ). When in doubt, the Swedish wording shall prevail.

 

Stockholm April 2017

The Board of Directors of Infant Bacterial Therapeutics AB (publ).

 

AGM documents in English

AGM Announcement

Nomination Committee

Proxy form AGM

 

AGM documents in Swedish

IBT kallelse AGM

Valberednings motivering

Fullmaktsformular AGM

April 5, 2017

Infant Bacterial Therapeutics AB (publ), (IBT) has been approved for listing on Nasdaq First North’s Premier segment.

Infant Bacterial Therapeutics AB (publ) (“IBT”), today traded on Nasdaq First North, has applied and been approved for listing on Nasdaq First North’s Premier segment. Companies which are listed on the Premier segment generally apply the same rules as the Nasdaq Stockholm main list, which means that going forward IBT will follow the more extensive requirements. In addition, the Premier segment rules include a recommendation to follow the Swedish Code for Corporate Governance, which IBT intends to implement as of the month of March 2017.

 

The first day for trading on Nasdaq First North Premier is March 14, 2017.  IBTs shares will continue to trade under the same ticker and ISIN code.

 

Staffan Strömberg, Chief Executive Officer at IBT, commented “The listing on Nasdaq First North Premier is a natural step towards the main market of Nasdaq Stockholm.”

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

About IBT:

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on March 10, 2017.

 

See Press Release in both English and Swedish

IBT Press Release 20170310 (English)

IBT Press Release 20170310 (Swedish)

March 10, 2017

IBT to present at Bio-Europe Spring 2017

Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Tuesday March 21, 2017 at Bio-Europe Spring Conference, Rare and Orphan Diseases track, at CCIB Convention Centre, Barcelona, Spain. The conference takes place between March 20-22, 2017.

 

Staffan Strömberg, President and Chief Executive Officer will represent the company in the presentation scheduled to begin at 11:30 local time.

 

About IBT:

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

See Press Release in both English and Swedish

IBT Press Release 20170301 (English)

IBT Press Release 20170301 (Swedish)

 

 

March 1, 2017

Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – December 31 2016

Message from the CEO

“During the month of June, the first patients were recruited and dosed in IBTs clinical study, IBP-9414, in the USA.  The last patient was recruited on January 23, 2017 and the results of the study are expected during the autumn of 2017.  During the month of December, IBT presented a further development project, IBP-1016, which is aimed to address the medical issues that arise in infants that are affected by gastroschisis, a rare and serious disease.

 

2017 is going to be an important year for IBT.  We will continue to build our organization so that we are well prepared for future challenges.  We expect to understand how agencies and experts view our new project IBP-1016 and we also expect to receive our Phase II (NCT02472769) results.

 

It is our long-term hope and ambition to offer the market pharmaceuticals that can save the lives of premature infants and I am optimistic about the future of IBT and our projects.”

 

Staffan Strömberg,

Chief Executive Officer

  

Financial summary 2016 

Significant events during the second half year 2016

July – December

-   In November, the independent safety monitoring committee (DSMB) reviewed the ongoing phase ll clinical trial in IBP-9414 (NCT02472769). Following the recommendation by the DSMB it was decided to continue the trial with the higher dose of IBT’s drug candidate IBP-9414 in the final group of patients

-   In December, IBT announced that it is in the early planning stages of another project, IBP-1016, to develop a drug to treat the consequences of gastroschisis, a rare life threatening and debilitating birth abnormality in infants

 

Significant events during the reporting period

January-December

-   The Annual General Meeting decided on repayment of conditional shareholder contributions by offsetting previously received group contributions by SEK 20.6m

-   BioGaia AB (publ) distributed its entire holding (94.5 % of shares and 96 % of votes) in IBT to BioGaia’s shareholders

-   IBT’s shares were listed on Nasdaq First North

-   IBT completed a guaranteed share issue which generated approximately SEK 89m after deduction of issue costs

-   In June, the first premature infants were enrolled and dosed in the Company’s phase ll clinical trial in IBP-9414 (NCT02472769)

 

Significant events after the reporting period

 

-   In January 2017, all 120 patients were included in the Company’s phase ll clinical trial in IBP-9414 (NCT02472769)

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

Publication

The information in this Interim Report is such which IBT is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North.

The information was submitted for publication, by the CEO, at 08.00 a.m. CET on February 14, 2017.

 

About IBT:

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.

www.ibtherapeutics.com

 

See Press release in both English and Swedish

IBT Press Release 20170214 (English)

IBT Press Release 20170214 (Swedish)

 

See the Year-End Report 2016 in both English and Swedish

IBT Year-End Report 2016 (English)

IBT Year-End Report 2016 (Swedish)

February 14, 2017

Last patient enrolled in IBT’s Phase 2 study

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed.

 

The Phase 2 study (ClinicalTrial.gov identifier: NCT02472769), which is part of IBT´s NEC prevention development program, is a randomized, double blind, parallel-group, dose escalation placebo-controlled multicenter study performed at neonatal intensive care units in the USA. The aim of the study is to investigate the safety and tolerability of two doses of the drug candidate (IBP-9414) administered to preterm infants. One-hundred and twenty (120) premature infants with birth weights ranging from 500g to 2,000g are included in the study. All patients in the study are treated with IBP-9414 or placebo for 14 days. The study ends after the last infant has been followed up for 6 months after the last dose administered.

 

Staffan Strömberg, Chief Executive Officer of IBT, commented "Reaching this milestone within the expected time frame is the result of diligent work by the study investigators and our own staff. We are pleased to have reached this goal considering the urgent need for a preventive therapy against this fatal disease NEC.”

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease program for the unmet medical need gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.50 CET on 24 January 2017.

 

See Press Release in both English and Swedish

IBT Press Release 20170124 (English)

IBT Press Release 20170124 (Swedish)

January 24, 2017

IBT to present at 9th Annual Biotech Showcase 2017

 

Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Wednesday January 11, 2017 at the Biotech Showcase 9th Annual Conference at the Hilton San Francisco Union Square, 333 O'Farrell St, San Francisco. The conference takes place between Jan. 9-11, 2017.

 

Staffan Strömberg, President and Chief Executive Officer will represent the company in the presentation scheduled to begin at 11:30 am Pacific Time.

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme for the unmet medical need Gastroschisis-Related Intestinal Dysfunction (“GRID”), a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

 

IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.

 

 

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

www.ibtherapeutics.com

 

See Press Release in both English and Swedish

IBT Press Release 20161215 (English)

IBT Press Release 20161215 (Swedish)

 

December 15, 2016

IBT adds new indication for Gastroschisis-Related Intestinal Dysfunction

Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, is in the early planning stages of developing a drug to treat gastroschisis-related intestinal dysfunction (“GRID”) using its live bacterial technology based on Lactobacillus reuteri.

 

GRID is a direct consequence of gastroschisis, a rare, life-threatening and debilitating birth abnormality in late preterm infants where the infant is born with externalized intestines. Infants suffering from GRID have a greatly increased risk of sepsis and liver cholestasis. GRID represents an area of significant unmet medical need with no definitive treatment available. Therefore, post-operative management of gastroschisis is largely aimed at overcoming the significant morbidity related to the reduction in gut motility and consequent feeding intolerance necessitating the prolonged requirement for parenteral nutrition. It is common for neonates born with gastroschisis to have typically an extended hospital stay of 1-5 months thereby causing significant burden to the healthcare system.

 

Based on Lactobacillus reuteri's known anti-pathogen and anti-inflammatory effects as well as effects on gut motility, and building on its knowledge from necrotizing enterocolitis (“NEC”), IBT believes Lactobacillus reuteri will have significant benefits in the treatment of GRID.

 

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Currently, IBT’s lead clinical programme is focused on developing the drug candidate, IBP-9414, using Lactobacillus reuteri to prevent necrotizing enterocolitis (“NEC”), a fatal disease that afflicts premature infants. IBT is listed on Nasdaq First North with Erik Penser Bank as Certified Adviser.

 

For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

www.ibtherapeutics.com

 

See Press Release in both English and Swedish

IBT Press Release 20161214 (English)

IBT Press Release 20161214 (Swedish)

December 14, 2016

Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study

 

IBT announces that the second and last planned evaluation of safety data by the independent Data Safety Monitoring Board (DSMB), in the ongoing Phase II clinical study, was performed on November 18th. The DSMB concluded that there were no objections to dose escalation into the final cohort of the smallest  premature babies, who will be dosed with the highest dose of IBT´s drug candidate IBP-9414.

 

"We are very pleased that we now have 90 of the 120 premature babies recruited and that the study is progressing according to plan. This is another major milestone in the development of a new pharmaceutical for this very sensitive group of patients”, says Staffan Strömberg, CEO IBT.

 

The Phase ll trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants. The multicenter trial is being conducted in a number of neonatal intensive care units in the US and will enroll 120 premature infants in total.

 

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

 

See Press Release in both English and Swedish

IBT Press Release 20161121 (English)

IBT Press Release 20161121 (Swedish)

November 21, 2016

Infant Bacterial Therapeutics AB appoints new CFO

Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role. Michael Owens will continue as financial controller of the company.

 

Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co., Nordea Investment Management AB and Nordea Bank AB.  In his role as CFO, Daniel will be responsible for overseeing capital and financing strategies, accounting and investor relations.

 

- We welcome Daniel to IBT. Our current operational focus is on the on-going US phase-II clinical trial. Next year will hold important new challenges and we are therefore very pleased to have Daniel on board to contribute to the development of IBT, says Staffan Strömberg CEO.

 

More information about the IBT Team is available here

 

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

 

See Press Release in both English and Swedish

IBT Press Release 20161012 (English)

IBT Press Release 20161012 (Swedish)

October 12, 2016

Infant Bacterial Therapeutics AB (publ), (IBT) Interim report January 1 – June 30 2016

 

Message from the CEO

“In June we announced that the first premature infant had been enrolled and dosed in the Company´s Phase ll clinical trial. This Phase ll trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants. The multicenter trial is being conducted in a number of neonatal intensive care units in the US and will enroll 120 premature infants in total. The first planned independent Data Safety Monitoring Board (DSMB) evaluation of safety data was performed on August 12th. The DSMB concluded that there were no objections to dose escalation based on the information provided to the DSMB.

We are very pleased that the trial has begun and is progressing according to plan. This is another major milestone in the development of a new pharmaceutical for this very sensitive group of patients.”

 

Staffan Strömberg,

Chief Executive Officer

 

Financial summary

Financial Summary

Significant events during the first six months

  • ●   Annual General Meeting decided on 8 February on repayment of conditional shareholder contributions by offsetting previously received group contributions by SEK 20.6m
  • ●   BioGaia AB (publ) distributed its entire holding (94.5 % of shares and 96 % of votes) in IBT to BioGaia’s shareholders
  • ●   IBT’s shares were listed on Nasdaq First North
  • ●   IBT completed a guaranteed share issue which generated approximately SEK 89m after deduction of issue costs
  • ●   The first premature infant has been enrolled and dosed in the Company’s Phase ll clinical trial

 

 

Significant events after the reporting period 

  • ●   There were no significant events after the reporting period prior to the date of publication of this interim report

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

Publication

The information in this Interim Report is such which IBT is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North.

The information was submitted for publication, by the CEO stated above, at 08.00 a.m. CET on 19 August, 2016.

 

2016

Interim report January 1 - June 30 2016

Press Release + Interim report English version

Press release + Interim report Swedish version

 

August 19, 2016

Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial

 

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the first premature infant has been enrolled and dosed in the Company´s Phase 2 clinical trial. This Phase 2 trial is a randomized, double blind, parallel group, dose escalation, placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants.

 

This is the first trial in the clinical development of IBP-9414 for the prevention of the often fatal disease necrotizing enterocolitis which affects premature infants. The multicenter trial is being conducted in a number of neonatal intensive care units in the US and will enroll 120 premature infants.

 

More information about the clinical trial can be found on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02472769).

 

Staffan Strömberg, Chief Executive Officer of IBT, comments, "We are very excited to have started the study and to now have the first baby included. This is an important milestone in our development of this potentially life-saving new drug.”

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm, Sweden

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

See Press Release in both English and Swedish

IBT Press Release 20160607 (English)

IBT Press Release 20160607 (Swedish)

June 7, 2016

IBT’s rights issue fully subscribed

 

The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) rights issue, for which the subscription period ended on 23 May 2016, indicates that 3,575,583 shares, corresponding to approximately 97.5 percent of the offered shares, were subscribed for by exercise of subscription rights. Additionally, applications for subscription without subscription rights of 2,215,458 shares, corresponding to approximately 60.4 percent of the offered shares, have been received. Thus, the rights issue is fully subscribed. Through the rights issue, IBT will receive proceeds amounting to approximately SEK 100 million before transaction costs.

 

Those who have subscribed for shares without subscription rights will be allotted shares according to the principles outlined in the prospectus. Such subscribers who have been allotted shares without subscription rights are expected to be notified on 26 May 2016. Only those who are allotted shares will be notified.

 

Through the rights issue IBT’s  share capital increases by approximately SEK 1,000,000 from SEK 500,000 to approximately SEK 1,500,000 and the total number of shares increases by 3,669,092 from 1,834,546 to 5,503,638 when the rights issue is registered by the Swedish Companies Registration Office.

 

The final day for trading in paid subscribed shares (BTAs) was 25 May 2016. The new shares subscribed for with subscription rights are expected to start trading on Nasdaq First North on 29 May 2016, and the shares subscribed for without subscription rights on 31 May 2016.

 

Financial and legal advisors

Carnegie Investment Bank is financial advisor and Advokatfirman Vinge is legal advisor to IBT.

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, chairman, phone: +46 8 410 145 55

 

 

Infant Bacterial Therapeutics AB (publ)

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

IBT discloses this information in accordance with Swedish Securities Market Act. The information was provided for publication at 8.00 AM on 26 May 2016.

 

 

IMPORTANT INFORMATION

This press release is not a prospectus or an offer to subscribe for shares in IBT and an investor shall not subscribe for or purchase any securities, except on the basis of information provided in the prospectus.

This press release may not be made public, released or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, Singapore, South Africa or New Zealand or in any other jurisdiction in which the distribution of this press release would be unlawful. Further, this press release does not constitute an offer to sell new shares, paid subscribed for shares ("BTA") or subscription rights to any person in any jurisdiction in which it is unlawful to make such offer to such person or where such action would require additional prospectuses, registration or other measures other than those pursuant to Swedish law. The prospectus, application forms and other documents associated with the rights issue may not be distributed in or to any country where such distribution or the rights issue would require such measures set forth in the preceding sentence or be in violation of the regulations of such country.

The new shares, BTAs and subscription rights have not been recommended by a United States federal or state securities commission or regulatory authority. No new shares, BTAs, subscription rights or other securities issued by IBT have been or will be registered under the U.S. Securities Act of 1933, as amended, or under the securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, BTAs, subscription rights or other securities issued by IBT may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration. The securities issued in the rights issue will not be offered to the public in the United States.

IBT has not authorized any offer of securities to the public in any country in the European Economic Area ("EEA") other than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC (the "Prospectus Directive") (each, a "Relevant Member State"), no action has been undertaken and will not be undertaken to make an offer of securities to the public requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States to (a) any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) any person falling within Article 3(2) of the Prospectus Directive.

The rights issue is only directed at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). The securities issued in the rights issue will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

 

 

See Press Release in both English and Swedish

IBT Press Release 20160526 (English)

IBT Press Release 20160526 (Swedish)

May 26, 2016

Prospectus relating to IBT’s rights issue published

To access the press release, please read the following disclaimer here.

April 27, 2016

IBT announces fully underwritten SEK 100 million rights issue

To access the press release, please read the following disclaimer here.

April 27, 2016

IBT receives Rare Pediatric Disease Designation from FDA for drug candidate

Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the U.S. Food and Drug Administration (FDA) has awarded IBT Rare Pediatric Disease Designation for its drug candidate IBP-9414, intended for the prevention necrotizing enterocolitis in premature infants.

 

Rare Pediatric Disease Designation is intended to encourage development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases. Having obtained the Rare Pediatric Disease Designation, FDA may award IBT a priority review voucher. A priority review voucher means that FDA ought to handle a drug application faster than normal.

 

Staffan Strömberg, Chief Executive Officer of IBT, commented, “The fact that FDA has given IBP-9414 Rare Pediatric Disease Designation, confirms how important it is to reach our goal that fewer premature babies shall be affected by the deadly disease necrotizing entercolitis, whilst at the same time this can reduce the time for this product to reach the market.”

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, Chairman of the Board, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

See Press Release in both Swedish and English:

 

IBT Press Release 20160331 (English)

IBT Press Release 20160331 (Swedish)

March 31, 2016

Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description

Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser Bankaktiebolag as Certified Adviser. The listing is part of the distribution of all of BioGaia AB’s (publ) shares in IBT to BioGaia’s shareholders, which was resolved at the extraordinary general meeting of BioGaia on 18 March 2016.

 

A company description has been prepared in connection with the listing and is available on IBT’s website, www.ibtherapeutics.com

 

 

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

 

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

 

See Press Release in both Swedish and English:

IBT Press Release 20160321 (Swedish)

IBT Press Release 20160321 (English)

March 21, 2016

Proposal for distribution and separate listing of Infant Bacterial Therapeutics from BioGaia

The board of directors of parent company BioGaia AB (publ) has resolved to propose to an Extraordinary General Meeting in BioGaia on 18 March 2016 to distribute the shares in the subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") to the shareholders of BioGaia. In connection with the execution of the dividend, IBT will apply for a listing of its series B shares on Nasdaq First North. To finance IBT’s first clinical trial, the company has, as previously communicated, a capital need of approximately SEK 100 million, which is planned to be raised through a rights issue with preferential rights for IBT’s shareholders during the second quarter 2016.

 

Read more the official BioGaia press release here

February 19, 2016

IBT has U.S. IND open and Swedish CTA approved for clinical study

IBT announces today that the IND (Investigational New Drug) for the prevention of necrotizing enterocolitis (NEC), has been accepted by the FDA (U.S. Food and Drug Administration). Furthermore, IBT has received approval from the MPA (Medical Product Agency) to conduct its clinical trial in Sweden.

Read the official IBT press release here Read the official BioGaia press release here

January 8, 2016

IBT receives additional funding from BioGaia

Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520 000 US dollars.

Read the official IBT press release here Read the official BioGaia press release here

March 26, 2015

Orphan Drug Designation in Europe

Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus reuteri for the prevention of necrotizing enterocolitis in Europe.
Read the official press release here

February 23, 2015

FDA approves orphan drug designation

Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request.
Read the official press release here

February 21, 2014

BioGaia invests in a drug against NEC

The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly fatal disease Necrotising Enterocolitis (NEC), which affects premature infants. BioGaia will invest SEK 42 million in the project over a two-year period. The project will be driven by BioGaia’s subsidiary Infant Bacterial Therapeutics (IBT), of which 9% is owned by the company’s President, Staffan Strömberg, and its Research Director, Eamonn Connolly. The remaining 91% is owned by BioGaia.
Read the official press release here

February 21, 2014